Sean McClain founded Absci in 2011, a generative AI drug creation company developing better biologics, creating them cheaper and faster. He grew it from a basement E. coli lab to a public company partnering with AstraZeneca, AMD, Caltech, and Gates Foundation. Absci built a platform combining generative AI with high-throughput wet-lab data for rapid drug validation. Sean led two firsts: producing full-length antibodies in E. coli and designing new antibodies using zero-shot generative AI. Absci tests hundreds of thousands of AI-designed antibodies weekly. In 2025, they began dosing the first AI-designed IBD drug in clinical trials—a major milestone. They're also developing breakthrough antibodies targeting HIV-1's previously untargetable "caldera" region, created entirely using AI.